<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101477</url>
  </required_header>
  <id_info>
    <org_study_id>98-3441A3</org_study_id>
    <nct_id>NCT01101477</nct_id>
  </id_info>
  <brief_title>Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation</brief_title>
  <official_title>Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation: Determining the Optimal Titrating Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flexible bronchoscopy (FB) sedation requires keeping sedative level in a narrow window to
      prevent over or under sedation. Sedative drug titration according to subjective adjustment by
      individual physician may cause unsteady drug concentration. Target controlled infusion (TCI)
      has been provided a precise pharmacokinetic control of propofol, direct control the effect
      side, (eg. Brain) concentration (Ce), and been applied in surgical anesthesia and variable
      procedure sedation. We designed this pilot study to evaluate the optimal regimen of TCI in FB
      sedation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Propofol is ideal for bronchoscopy sedation because of its fast onset and quick recovery
      effect. Our research and reports from different investigators demonstrate that patients
      received propofol sedation recover fast with excellent satisfaction for bronchoscopy.
      However, the amount of propofol for induction and maintenance is calculated simply by
      patient's body weight and physicians' experience. For those non-anesthesiologists, who
      perform sedative work outside the operating room, and inexperienced anesthesiologist without
      fully considering the individual pharmacokinetic and pharmacodynamic differences may generate
      unstable drug plasma concentration and increase cardio-respiration suppression. Therefore, a
      manner which can assess and measure objectively individual pharmacokinetic differences may
      improve the sedative quality and decrease the complication rate.

      A model called &quot;Target-controlled infusion&quot;(TCI), built from massive pharmacokinetic samples
      of propofol, could now give precise pharmacokinetic control. Several pharmacokinetic models
      built-in in TCI, includes the Schnider model which use concentration of effect site (Ce, the
      propofol concentration in the brain) as the sedative guide. The model integrates individual
      variants of age, height, weight and gender to calculate the infusion profile to achieve
      predetermined steady &quot;target effect site concentration&quot; (Cet). Because of the unique
      consideration of individual pharmacokinetic variants and Ce targeting, TCI provides
      predictable sedative level and is suitable for procedures requiring narrowing therapeutic
      level. Beside general anesthesia, TCI has been applied in breast biopsy, upper
      gastrointestinal endoscopic ultrasound and endoscopic retrograde cholangiopancreatography at
      outpatient clinic. According to these evidences, there is potential role of TCI in
      bronchoscopic sedation.

      Based on current evidence and our experience, we design this study to evaluate the optimal
      regimen for induction and procedure during bronchoscopy. We hope this study could provide the
      more safety and efficient bronchoscopic sedation for patients and physicians.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Hypoxemia(SPaO2&lt;80%) episodes occured significantly in the arm titration by 0.5ug/ml
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients With Hypoxemia During Flexible Bronchoscopy</measure>
    <time_frame>During sedative induction and bronchoscopy</time_frame>
    <description>Hypoxemia is defined as:
Oxyhemoglobin saturation (SPO2) is less than 90 % with any duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Changes in Target Effect Site Concentration During Flexible Bronchoscopy</measure>
    <time_frame>During sedative induction and bronchoscopy</time_frame>
    <description>The investigator will titrate the target effect site concentration (Cet) during bronchoscopy according to protocol to keep stable vital signs and sedative levels. The numbers of adjustment will be recorded to show which regimen required less adjustment to keep stable sedative levels and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Recovery Time to Orientation</measure>
    <time_frame>after bronchosocpy</time_frame>
    <description>The recovery time to orientation was defined as the time between finishing bronchoscopy to the time when the patients could spontaneously open their eyes, recall their date of birth, and correctly perform finger-nose test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Doses of Propofol During Induction and Overall Procedures</measure>
    <time_frame>after bronchoscopy</time_frame>
    <description>The dosses of propofol used during induction and overall flexible bronchoscopy will be recored from the screen of the TCI pump.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cooperation of Patients From the View of Bronchoscopists</measure>
    <time_frame>After bronchoscopy</time_frame>
    <description>After the bronchoscopy, the bronchoscopist will be asked by 10-point Verbal Analogus Scale (0: the best cooperation, 10: the worst cooperation) to express how they fell about the cooperation of patients undergoing the bronchoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Global Tolerance for Flexible Bronchoscopy</measure>
    <time_frame>After recovery</time_frame>
    <description>After the recovery, patients will be asked about the tolerance of bronchoscopy performed to them by 10-point Verbal Analogus Scale (0: best tolerance, 10: worst tolerance)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Flexible Bronchoscopy</condition>
  <arm_group>
    <arm_group_label>Titration by target effect site concentration (Cet) 0.5μg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Titration by Cet 0.2μg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Titration by Cet 0.1μg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TCI titration by different Cet.</intervention_name>
    <description>Induction:
After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial&quot; Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale &quot;OAA/S&quot; every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.
If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.
Maintenance:
The Cet will be increased according to the assigned regimens if:
Patients become irritant and interfere procedures.
Patients open eyes or talk to express uncomfortable.
The Cet will be decreased if:
Systolic blood pressure is less than 90mmHg;
Mean arterial blood pressure is less than 65mmHg;
Oxyhemoglobin saturation is less than 90 %
with any duration.</description>
    <arm_group_label>Titration by target effect site concentration (Cet) 0.5μg/ml</arm_group_label>
    <arm_group_label>Titration by Cet 0.2μg/ml</arm_group_label>
    <arm_group_label>Titration by Cet 0.1μg/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 years old or more) required elective flexible bronchoscopy and
             sedation.

        Exclusion Criteria:

          -  American Society of Anesthesiologists classification of physical status 4 and 5,
             including hepatic or renal failure, severe obstructive sleep apnea and severe chronic
             obstructive pulmonary disease.

          -  Mallampati score 4 or 5.

          -  Significant Central nervous system disorders or other factors contributing to access
             consciousness difficultly.

          -  Men with body mass index(BMI) large than 42，Females with BMI large than 35.

          -  Allergic history to study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting-Yu Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic Medicine, Chang Gung Memorial hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Thoracic Medicine, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Fanti L, Agostoni M, Arcidiacono PG, Albertin A, Strini G, Carrara S, Guslandi M, Torri G, Testoni PA. Target-controlled infusion during monitored anesthesia care in patients undergoing EUS: propofol alone versus midazolam plus propofol. A prospective double-blind randomised controlled trial. Dig Liver Dis. 2007 Jan;39(1):81-6. Epub 2006 Oct 16.</citation>
    <PMID>17049322</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2010</study_first_posted>
  <results_first_submitted>November 5, 2011</results_first_submitted>
  <results_first_submitted_qc>November 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>November 5, 2011</last_update_submitted>
  <last_update_submitted_qc>November 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>林定佑</investigator_full_name>
    <investigator_title>Attending physician, Lecture of Medicine, Division of Thoracic Medicine</investigator_title>
  </responsible_party>
  <keyword>Target-controlled infusion,</keyword>
  <keyword>bronchoscopy,</keyword>
  <keyword>sedation,</keyword>
  <keyword>propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients undergoing elective flexible bronchoscopy (FB) and sedation were screened for enrolment at the bronchoscopic room on the day of exam.</recruitment_details>
      <pre_assignment_details>If patients or accompanying family refused to paticipate anytime before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Titration by Target Effect Site Concentration (Cet) 0.5μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="P2">
          <title>Titration by Cet 0.2μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="P3">
          <title>Titration by Cet 0.1μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Titration by Target Effect Site Concentration (Cet) 0.5μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="B2">
          <title>Titration by Cet 0.2μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="B3">
          <title>Titration by Cet 0.1μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="13.0"/>
                    <measurement group_id="B2" value="62.6" spread="13.5"/>
                    <measurement group_id="B3" value="63.4" spread="14.4"/>
                    <measurement group_id="B4" value="62.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients With Hypoxemia During Flexible Bronchoscopy</title>
        <description>Hypoxemia is defined as:
Oxyhemoglobin saturation (SPO2) is less than 90 % with any duration</description>
        <time_frame>During sedative induction and bronchoscopy</time_frame>
        <population>The participants who received intervention completely were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Titration by Target Effect Site Concentration (Cet) 0.5μg/ml</title>
            <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
          </group>
          <group group_id="O2">
            <title>Titration by Cet 0.2μg/ml</title>
            <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
          </group>
          <group group_id="O3">
            <title>Titration by Cet 0.1μg/ml</title>
            <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Hypoxemia During Flexible Bronchoscopy</title>
          <description>Hypoxemia is defined as:
Oxyhemoglobin saturation (SPO2) is less than 90 % with any duration</description>
          <population>The participants who received intervention completely were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The patients with at lease one episode of hypoxemia (SPaO2&lt;90%) during FB were analyzed by Chi-square test. P value less 0.05 means significance, 2-sided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Changes in Target Effect Site Concentration During Flexible Bronchoscopy</title>
        <description>The investigator will titrate the target effect site concentration (Cet) during bronchoscopy according to protocol to keep stable vital signs and sedative levels. The numbers of adjustment will be recorded to show which regimen required less adjustment to keep stable sedative levels and vital signs.</description>
        <time_frame>During sedative induction and bronchoscopy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Recovery Time to Orientation</title>
        <description>The recovery time to orientation was defined as the time between finishing bronchoscopy to the time when the patients could spontaneously open their eyes, recall their date of birth, and correctly perform finger-nose test.</description>
        <time_frame>after bronchosocpy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Doses of Propofol During Induction and Overall Procedures</title>
        <description>The dosses of propofol used during induction and overall flexible bronchoscopy will be recored from the screen of the TCI pump.</description>
        <time_frame>after bronchoscopy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cooperation of Patients From the View of Bronchoscopists</title>
        <description>After the bronchoscopy, the bronchoscopist will be asked by 10-point Verbal Analogus Scale (0: the best cooperation, 10: the worst cooperation) to express how they fell about the cooperation of patients undergoing the bronchoscopy.</description>
        <time_frame>After bronchoscopy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Global Tolerance for Flexible Bronchoscopy</title>
        <description>After the recovery, patients will be asked about the tolerance of bronchoscopy performed to them by 10-point Verbal Analogus Scale (0: best tolerance, 10: worst tolerance)</description>
        <time_frame>After recovery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the starting of induction to patients leaving the bronchoscopic room after recovery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Titration by Target Effect Site Concentration (Cet) 0.5μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="E2">
          <title>Titration by Cet 0.2μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
        <group group_id="E3">
          <title>Titration by Cet 0.1μg/ml</title>
          <description>The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>oxyhemoglobin saturation (SpO2) less than 80%</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ting-Yu Lin</name_or_title>
      <organization>Chang Gung Memorial Hospital</organization>
      <phone>886 3 3281200 ext 5108</phone>
      <email>yuebaoyuebao@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

